Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$20.92

0.21 (1.01%)

04:55
12/11/18
12/11
04:55
12/11/18
04:55

Portola Pharmaceuticals management to meet with William Blair

Meeting to be held in Boston on December 11 hosted by William Blair.

  • 11

    Dec

  • 31

    Dec

PTLA Portola Pharmaceuticals
$20.92

0.21 (1.01%)

09/12/18
WBLR
09/12/18
NO CHANGE
WBLR
Outperform
Portola manufacturing review timeline encouraging, says William Blair
Portola Pharmaceuticals last night announced that the FDA assigned a PDUFA date of December 31, 2018, for the recently submitted prior approval supplement for the generation 2 manufacturing process of Andexxa, equating to a four-month review period, William Blair analyst Matt Phipps tells investors in a research note. Portola management had conservatively guided to a six-month review, the analyst notes. He's encouraged by this review timeline, pointing out that approval in 2018 would provide Portola with full commercial supply for Q1 of 2019. Phipps remains confident in the potential of Andexxa to achieve blockbuster sales and believes Andexxa alone is worth "significantly more than the company at current price levels." He keeps an Outperform rating on Portola Pharmaceuticals.
10/02/18
WBLR
10/02/18
NO CHANGE
WBLR
Outperform
William Blair says market 'significantly' undervaluing Portola's Andexxa
William Blair analyst Matt Phipps says a call he hosted yesterday with Jean Marie Connors, M.D., associate professor of medicine and medical director of the hemostatic and antithrombotic stewardship program and anticoagulation management service at Brigham and Women's Hospital, to discuss the use of reversal agents in patients who experience major bleeding events on anticoagulants such as factor Xa inhibitors, highlighted the "significant opportunity" for Portola Pharmaceuticals' Andexxa. The call put a spotlight on the "sizable market opportunity" for Andexxa once the commercial supply amendment is approved, Phipps tells investors in a research note. The analyst continues to believe Andexxa has blockbuster potential based on the "significant and growing market opportunity" for the reversal of factor Xa inhibitors. Further, he sees an opportunity for increased utilization following approval in patients requiring emergency surgery, potentially increasing the average patients per month treated with Andexxa. The analyst believes the market continues to "significantly undervalue" the potential of Andexxa, as well as near-term catalysts for Portola, including expanding commercialization across the United States and regulatory approval in Europe. He keeps an Outperform rating on the shares.
11/07/18
SBSH
11/07/18
NO CHANGE
Target $49
SBSH
Buy
Citi revisits bull case on Portola with shares down 50%
Citi analyst Yigal Nochomovitz says shares of Portola Pharmaceuticals are down 50% since the Q2 earnings call on a "very disappointing" launch for Bevyxxa. The stock is now heavily levered to a successful launch of Andexxa, the analyst tells investors in a research note. With the stock now at $20, now is the time to re-articulate the Andexxa bull case, a lifesaving emergency therapy, says Nochomovitz. He believes Andexxa can be a $1B drug in the U.S., which he estimates is worth $42 per share alone. The analyst keeps a Buy rating on Portola Pharmaceuticals while trimming his price target for the shares to $49 from $50.
11/08/18
OPCO
11/08/18
NO CHANGE
Target $30
OPCO
Outperform
Portola Pharmaceuticals price target lowered to $30 from $60 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Portola Pharmaceuticals to $30 from $60 after making changes to his model following the company's conference call, namely removing all Bevyxxa revenues, slowing the ramp of Andexxa, lowering the peak sales of Andexxa, and increasing expenses. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/19/19
11/19
16:20
11/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$162.87

-0.04 (-0.02%)

16:19
11/19/19
11/19
16:19
11/19/19
16:19
Hot Stocks
M&T Bank boosts quarterly dividend 10% to $1.10 per share »

M&T Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESE

Esco Technologies

$86.70

1.93 (2.28%)

16:19
11/19/19
11/19
16:19
11/19/19
16:19
Earnings
Esco Technologies reports Q4 adj. EPS $1.09, two estimates $1.06 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

CRSP

Crispr Therapeutics

$68.46

9.94 (16.99%)

16:19
11/19/19
11/19
16:19
11/19/19
16:19
Syndicate
Crispr Therapeutics files to sell 4.25M shares of common stock »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 07

    Dec

AVID

Avid Technology

$7.77

0.18 (2.37%)

16:18
11/19/19
11/19
16:18
11/19/19
16:18
Hot Stocks
Avid Technology sees FY20 adjusted EBITDA $66M-$74M »

Sees FY20 free cash flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

SPCB

SuperCom

$0.66

0.0052 (0.80%)

16:18
11/19/19
11/19
16:18
11/19/19
16:18
Hot Stocks
SuperCom receives Nasdaq listing notice due to late form 20-F »

SuperCom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVID

Avid Technology

$7.77

0.18 (2.37%)

16:17
11/19/19
11/19
16:17
11/19/19
16:17
Earnings
Avid Technology sees FY20 adjusted EPS 84c-93c, consensus 73c »

Sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

FLNT

Fluent

$1.42

0.11 (8.40%)

16:17
11/19/19
11/19
16:17
11/19/19
16:17
Hot Stocks
Fluent announces $5M shares repurchase program »

Fluent announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVYA

Avaya

$12.11

-0.22 (-1.78%)

16:17
11/19/19
11/19
16:17
11/19/19
16:17
Hot Stocks
Avaya names Anthony Bartolo as Chief Product Officer »

Avaya Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
11/19/19
11/19
16:17
11/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WINS

Wins Finance

$10.55

-0.45 (-4.09%)

16:16
11/19/19
11/19
16:16
11/19/19
16:16
Hot Stocks
Wins Finance receives listing qualifications letters from Nasdaq »

Wins Finance Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
11/19/19
11/19
16:16
11/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSKN

Strata Skin Sciences

$2.30

-0.3 (-11.54%)

16:15
11/19/19
11/19
16:15
11/19/19
16:15
Hot Stocks
Strata Skin Sciences regains compliance with Nasdaq listing rules »

STRATA Skin Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$5.17

-0.01 (-0.19%)

16:15
11/19/19
11/19
16:15
11/19/19
16:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$98.02

5.32 (5.74%)

16:14
11/19/19
11/19
16:14
11/19/19
16:14
Initiation
Alnylam initiated  »

Oppenheimer starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 07

    Dec

  • 04

    Feb

AKCA

Akcea Therapeutics

$19.06

0.31 (1.65%)

, IONS

Ionis Pharmaceuticals

$58.03

0.26 (0.45%)

16:13
11/19/19
11/19
16:13
11/19/19
16:13
Hot Stocks
Akcea Therapeutics announces closing of licensing agreement with Pfizer »

Akcea Therapeutics…

AKCA

Akcea Therapeutics

$19.06

0.31 (1.65%)

IONS

Ionis Pharmaceuticals

$58.03

0.26 (0.45%)

PFE

Pfizer

$37.64

0.43 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 22

    Nov

  • 07

    Dec

ENDP

Endo

$4.44

-0.02 (-0.45%)

16:11
11/19/19
11/19
16:11
11/19/19
16:11
Hot Stocks
Endo announces FDA accepted for review the original BLA for CCH »

Endo International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNNE

Cannae Holdings

$36.57

-0.27 (-0.73%)

16:10
11/19/19
11/19
16:10
11/19/19
16:10
Hot Stocks
Cannae Holdings names Richard Massey as new CEO »

Cannae Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$22.72

0.09 (0.40%)

16:10
11/19/19
11/19
16:10
11/19/19
16:10
Initiation
Amarin initiated  »

Amarin initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

JNJ

Johnson & Johnson

$134.83

-0.01 (-0.01%)

16:10
11/19/19
11/19
16:10
11/19/19
16:10
Initiation
Johnson & Johnson initiated  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

DAN

Dana

$16.81

0.105 (0.63%)

16:09
11/19/19
11/19
16:09
11/19/19
16:09
Initiation
Dana initiated  »

Dana initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$28.62

-1.54 (-5.11%)

16:08
11/19/19
11/19
16:08
11/19/19
16:08
Earnings
Urban Outfitters reports Q3 EPS 56c, consensus 57c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 05

    Dec

ALNY

Alnylam

$97.88

5.18 (5.59%)

16:08
11/19/19
11/19
16:08
11/19/19
16:08
Initiation
Alnylam initiated  »

Alnylam initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 07

    Dec

  • 04

    Feb

DFFN

Diffusion Pharmaceuticals

$0.22

-0.0013 (-0.58%)

16:08
11/19/19
11/19
16:08
11/19/19
16:08
Hot Stocks
Diffusion Pharmaceuticals announces increased survival in TSC plus SOC trial »

Diffusion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWM

New Media

$6.33

0.005 (0.08%)

, GCI

Gannett

$9.68

(0.00%)

16:06
11/19/19
11/19
16:06
11/19/19
16:06
Hot Stocks
New Media, Gannett complete merger »

New Media Investment…

NEWM

New Media

$6.33

0.005 (0.08%)

GCI

Gannett

$9.68

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.